<p>Eton Pharmaceuticals, Inc.（纳斯达克代码：ETON - 获取免费报告）在覆盖该公司的五位分析师中获得了 “持有” 的共识推荐，Marketbeat 报道。两位股票研究分析师给予该股票 “卖出” 评级，三位分析师给予 “买入” 评级。在过去一年中，给予该股票评级的分析师的平均一年目标价为 29.6667 美元。</p>
<p>获取 <strong>Eton Pharmaceuticals</strong> 的提醒：</p>
<p>最近，一些分析师对 ETON 股票发表了评论。Zacks Research 在 11 月 13 日的研究报告中将 Eton Pharmaceuticals 的评级从 “持有” 下调至 “强烈卖出”。Weiss Ratings 在 10 月 8 日的报告中重申了对 Eton Pharmaceuticals 股票的 “卖出（d-）” 评级。最后，Wall Street Zen 在 12 月 13 日的报告中将 Eton Pharmaceuticals 的股票评级从 “买入” 下调至 “持有”。</p>
<p><strong>查看我们对 ETON 的最新分析</strong></p>
<h2>Eton Pharmaceuticals 的机构交易</h2>
<p>一些机构投资者和对冲基金最近买入和卖出了该股票的股份。阿拉斯加州财政部在第三季度新购入了 Eton Pharmaceuticals 的股份，价值约 30,000 美元。Ameritas Investment Partners Inc. 在第二季度新购入了 Eton Pharmaceuticals 的股份，价值约 37,000 美元。Quarry LP 在第三季度新购入了 Eton Pharmaceuticals 的股份，价值约 37,000 美元。Legal &amp; General Group Plc 在第二季度新购入了 Eton Pharmaceuticals 的股份，价值约 41,000 美元。最后，AlphaQuest LLC 在第一季度新购入了 Eton Pharmaceuticals 的股份，价值约 53,000 美元。目前，27.86% 的股票由机构投资者和对冲基金持有。</p>
<h2>Eton Pharmaceuticals 股票表现</h2>
<p>纳斯达克 ETON 周二开盘价为 16.57 美元。该公司的 50 日移动平均价格为 17.21 美元，200 日移动平均价格为 16.76 美元。该股票的市值为 4.4441 亿美元，市盈率为-66.28，贝塔值为 1.17。该公司的债务与股本比率为 1.19，速动比率为 1.25，流动比率为 1.63。Eton Pharmaceuticals 的 52 周低点为 11.09 美元，52 周高点为 23.00 美元。</p>
<p>Eton Pharmaceuticals（纳斯达克代码：ETON - 获取免费报告）最近于 11 月 6 日发布了季度财报。该公司报告的每股收益为（0.07）美元，低于共识预期的 0.13 美元（差距为 0.20 美元）。该公司季度收入为 2246 万美元，而分析师预期为 2047 万美元。Eton Pharmaceuticals 的净利润率为-9.50%，股本回报率为-11.32%。平均而言，股票分析师预计 Eton Pharmaceuticals 在当前财政年度将发布-0.14 的每股收益。</p>
<h2>Eton Pharmaceuticals 公司简介</h2>
<p>（获取免费报告）</p>
<p>Eton Pharmaceuticals, Inc 是一家专注于开发、生产和商业化针对罕见和服务不足疾病的仿制药和专有药品的专业制药公司。公司总部位于佛罗里达州西棕榈滩，利用其在激素疗法和复杂分子方面的专业知识，解决患者需求高、竞争有限的治疗领域。自 2016 年成立以来，Eton 一直致力于建立一个多元化的产品组合，将成熟的仿制药与针对性品牌产品相结合。</p>
<p>该公司的产品线包括甲状腺激素替代品，如干燥甲状腺和利奥甲状腺素，以及用于弓形虫病的吡美莫司片。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Eton Pharmaceuticals</li>
<li>请勿删除，立即阅读</li>
<li>投资者提醒：微型 “3 美元人工智能奇迹股票” 即将爆发</li>
<li>资本利得税是否可以扣除任何费用？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>最后的黄金牛市</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVRPTg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVRPTg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Eton Pharmaceuticals 吗？</h2>
<p>在考虑 Eton Pharmaceuticals 之前，你会想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前立即购买……而 Eton Pharmaceuticals 并不在名单上。</p>
<p>虽然 Eton Pharmaceuticals 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

ETON

<p>Eton Pharmaceuticals, Inc.（纳斯达克代码：ETON）获得了五位分析师的共识 “持有” 评级。两位分析师给予 “卖出” 评级，三位给予 “买入” 评级。平均一年目标价为 29.67 美元。最近的分析师行动包括 Zacks Research 将评级下调至 “强烈卖出”，Wall Street Zen 则维持 “持有” 评级。机构投资者持有该股票 27.86%。公司报告了第三季度的亏损，未能达到预期。Eton 专注于罕见疾病治疗，并拥有多样化的产品组合</p>

<p>Eton Pharmaceuticals, Inc. (NASDAQ:ETON - Get Free Report) has been given a consensus recommendation of &#34;Hold&#34; by the five analysts that are covering the company, Marketbeat reports. Two equities research analysts have rated the stock with a sell rating and three have given a buy rating to the company. The average 1-year price objective among analysts that have issued ratings on the stock in the last year is $29.6667.</p>
<div class="lb-trans"><p>Eton Pharmaceuticals, Inc.（纳斯达克代码：ETON - 获取免费报告）在覆盖该公司的五位分析师中获得了 “持有” 的共识推荐，Marketbeat 报道。两位股票研究分析师给予该股票 “卖出” 评级，三位分析师给予 “买入” 评级。在过去一年中，给予该股票评级的分析师的平均一年目标价为 29.6667 美元。</p>
</div><p>Get <strong>Eton Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Eton Pharmaceuticals</strong> 的提醒：</p>
</div><p>A number of analysts have recently commented on ETON shares. Zacks Research lowered Eton Pharmaceuticals from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research note on Thursday, November 13th. Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Eton Pharmaceuticals in a report on Wednesday, October 8th. Finally, Wall Street Zen lowered shares of Eton Pharmaceuticals from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday, December 13th.</p>
<div class="lb-trans"><p>最近，一些分析师对 ETON 股票发表了评论。Zacks Research 在 11 月 13 日的研究报告中将 Eton Pharmaceuticals 的评级从 “持有” 下调至 “强烈卖出”。Weiss Ratings 在 10 月 8 日的报告中重申了对 Eton Pharmaceuticals 股票的 “卖出（d-）” 评级。最后，Wall Street Zen 在 12 月 13 日的报告中将 Eton Pharmaceuticals 的股票评级从 “买入” 下调至 “持有”。</p>
</div><p><strong>Check Out Our Latest Analysis on ETON</strong></p>
<div class="lb-trans"><p><strong>查看我们对 ETON 的最新分析</strong></p>
</div><h2>Institutional Trading of Eton Pharmaceuticals</h2>
<div class="lb-trans"><h2>Eton Pharmaceuticals 的机构交易</h2>
</div><p>A number of institutional investors and hedge funds have recently bought and sold shares of the stock. State of Alaska Department of Revenue acquired a new position in Eton Pharmaceuticals during the 3rd quarter worth about $30,000. Ameritas Investment Partners Inc. bought a new position in shares of Eton Pharmaceuticals during the second quarter worth about $37,000. Quarry LP bought a new position in shares of Eton Pharmaceuticals during the third quarter worth about $37,000. Legal &amp; General Group Plc acquired a new position in shares of Eton Pharmaceuticals in the second quarter worth approximately $41,000. Finally, AlphaQuest LLC bought a new stake in Eton Pharmaceuticals in the first quarter valued at approximately $53,000. 27.86% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些机构投资者和对冲基金最近买入和卖出了该股票的股份。阿拉斯加州财政部在第三季度新购入了 Eton Pharmaceuticals 的股份，价值约 30,000 美元。Ameritas Investment Partners Inc. 在第二季度新购入了 Eton Pharmaceuticals 的股份，价值约 37,000 美元。Quarry LP 在第三季度新购入了 Eton Pharmaceuticals 的股份，价值约 37,000 美元。Legal &amp; General Group Plc 在第二季度新购入了 Eton Pharmaceuticals 的股份，价值约 41,000 美元。最后，AlphaQuest LLC 在第一季度新购入了 Eton Pharmaceuticals 的股份，价值约 53,000 美元。目前，27.86% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>Eton Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Eton Pharmaceuticals 股票表现</h2>
</div><p>NASDAQ ETON opened at $16.57 on Tuesday. The firm's fifty day moving average price is $17.21 and its two-hundred day moving average price is $16.76. The stock has a market cap of $444.41 million, a PE ratio of -66.28 and a beta of 1.17. The company has a debt-to-equity ratio of 1.19, a quick ratio of 1.25 and a current ratio of 1.63. Eton Pharmaceuticals has a fifty-two week low of $11.09 and a fifty-two week high of $23.00.</p>
<div class="lb-trans"><p>纳斯达克 ETON 周二开盘价为 16.57 美元。该公司的 50 日移动平均价格为 17.21 美元，200 日移动平均价格为 16.76 美元。该股票的市值为 4.4441 亿美元，市盈率为-66.28，贝塔值为 1.17。该公司的债务与股本比率为 1.19，速动比率为 1.25，流动比率为 1.63。Eton Pharmaceuticals 的 52 周低点为 11.09 美元，52 周高点为 23.00 美元。</p>
</div><p>Eton Pharmaceuticals (NASDAQ:ETON - Get Free Report) last released its quarterly earnings data on Thursday, November 6th. The company reported ($0.07) earnings per share for the quarter, missing the consensus estimate of $0.13 by ($0.20). The firm had revenue of $22.46 million for the quarter, compared to analyst estimates of $20.47 million. Eton Pharmaceuticals had a negative net margin of 9.50% and a negative return on equity of 11.32%. On average, equities analysts expect that Eton Pharmaceuticals will post -0.14 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Eton Pharmaceuticals（纳斯达克代码：ETON - 获取免费报告）最近于 11 月 6 日发布了季度财报。该公司报告的每股收益为（0.07）美元，低于共识预期的 0.13 美元（差距为 0.20 美元）。该公司季度收入为 2246 万美元，而分析师预期为 2047 万美元。Eton Pharmaceuticals 的净利润率为-9.50%，股本回报率为-11.32%。平均而言，股票分析师预计 Eton Pharmaceuticals 在当前财政年度将发布-0.14 的每股收益。</p>
</div><h2>Eton Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Eton Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.</p>
<div class="lb-trans"><p>Eton Pharmaceuticals, Inc 是一家专注于开发、生产和商业化针对罕见和服务不足疾病的仿制药和专有药品的专业制药公司。公司总部位于佛罗里达州西棕榈滩，利用其在激素疗法和复杂分子方面的专业知识，解决患者需求高、竞争有限的治疗领域。自 2016 年成立以来，Eton 一直致力于建立一个多元化的产品组合，将成熟的仿制药与针对性品牌产品相结合。</p>
</div><p>The company's product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.</p>
<div class="lb-trans"><p>该公司的产品线包括甲状腺激素替代品，如干燥甲状腺和利奥甲状腺素，以及用于弓形虫病的吡美莫司片。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Eton Pharmaceuticals</li>
<li>Do not delete, read immediately</li>
<li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li>
<li>Can Any Expenses Be Deducted From Capital Gains Tax?</li>
<li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li>
<li>The Last Gold Bull Market</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Eton Pharmaceuticals</li>
<li>请勿删除，立即阅读</li>
<li>投资者提醒：微型 “3 美元人工智能奇迹股票” 即将爆发</li>
<li>资本利得税是否可以扣除任何费用？</li>
<li>巴菲特、盖茨和贝索斯悄悄抛售股票——原因在这里</li>
<li>最后的黄金牛市</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVRPTg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=ETON"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Eton Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Eton Pharmaceuticals 吗？</h2>
</div><p>Before you consider Eton Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Eton Pharmaceuticals 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eton Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前立即购买……而 Eton Pharmaceuticals 并不在名单上。</p>
</div><p>While Eton Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Eton Pharmaceuticals 目前在分析师中获得 “持有” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Eton Pharmaceuticals, Inc.（纳斯达克股票代码：ETON）被券商给予平均 “持有” 评级